tetano
Editor, Senior Moderator
Cardiovasc Pathol. 2020 Apr 17;47:107228. doi: 10.1016/j.carpath.2020.107228. [Epub ahead of print]
Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019.
Geng YJ[SUP]1[/SUP], Wei ZY[SUP]2[/SUP], Qian HY[SUP]2[/SUP], Huang J[SUP]3[/SUP], Lodato R[SUP]4[/SUP], Castriotta RJ[SUP]5[/SUP].
Author information
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major health crisis, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having infected over a million people around the world within a few months of its identification as a human pathogen. Initially, SARS-CoV-2 infects cells in the respiratory system and causes inflammation and cell death. Subsequently, the virus spreads out and damages other vital organs and tissues, triggering a complicated spectrum of pathophysiological changes and symptoms, including cardiovascular complications. Acting as the receptor for SARS-CoV entering mammalian cells, angiotensin converting enzyme-2 (ACE2) plays a pivotal role in the regulation of cardiovascular cell function. Diverse clinical manifestations and laboratory abnormalities occur in patients with cardiovascular injury in COVID-19, characterizing the development of this complication, as well as providing clues to diagnosis and treatment. This review provides a summary of the rapidly appearing laboratory and clinical evidence for the pathophysiology and therapeutic approaches to COVID-19 pulmonary and cardiovascular complications.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Blood vessels; Coronavirus; Heart; Infection; Injury; Lung
PMID:32375085DOI:10.1016/j.carpath.2020.107228
Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019.
Geng YJ[SUP]1[/SUP], Wei ZY[SUP]2[/SUP], Qian HY[SUP]2[/SUP], Huang J[SUP]3[/SUP], Lodato R[SUP]4[/SUP], Castriotta RJ[SUP]5[/SUP].
Author information
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major health crisis, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having infected over a million people around the world within a few months of its identification as a human pathogen. Initially, SARS-CoV-2 infects cells in the respiratory system and causes inflammation and cell death. Subsequently, the virus spreads out and damages other vital organs and tissues, triggering a complicated spectrum of pathophysiological changes and symptoms, including cardiovascular complications. Acting as the receptor for SARS-CoV entering mammalian cells, angiotensin converting enzyme-2 (ACE2) plays a pivotal role in the regulation of cardiovascular cell function. Diverse clinical manifestations and laboratory abnormalities occur in patients with cardiovascular injury in COVID-19, characterizing the development of this complication, as well as providing clues to diagnosis and treatment. This review provides a summary of the rapidly appearing laboratory and clinical evidence for the pathophysiology and therapeutic approaches to COVID-19 pulmonary and cardiovascular complications.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Blood vessels; Coronavirus; Heart; Infection; Injury; Lung
PMID:32375085DOI:10.1016/j.carpath.2020.107228